MicroRNAs in islet immunobiology and transplantation

Antonello Pileggi, Dagmar Klein, Carmen Fotino, Valia Bravo-Egana, Samuel Rosero, Marco Doni, Michele Podetta, Camillo Ricordi, R. Damaris Molano, Ricardo L. Pastori

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The ultimate goal of diabetes therapy is the restoration of physiologic metabolic control. For type 1 diabetes, research efforts are focused on the prevention or early intervention to halt the autoimmune process and preserve β cell function. Replacement of pancreatic β cells via islet transplantation reestablishes physiologic β cell function in patients with diabetes. Emerging research shows that microRNAs (miRNAs), noncoding small RNA molecules produced by a newly discovered class of genes, negatively regulate gene expression. MiRNAs recognize and bind to partially complementary sequences of target messenger RNA (mRNA), regulating mRNA translation and affecting gene expression. Correlation between miRNA signatures and genome-wide RNA expression allows identification of multiple miRNA-mRNA pairs in biological processes. Because miRNAs target functionally related genes, they represent an exciting and indispensable approach for biomarkers and drug discovery. We are studying the role of miRNA in the context of islet immunobiology. Our research aims at understanding the mechanisms underlying pancreatic β cell loss and developing clinically relevant approaches for preservation and restoration of β cell function to treat insulin-dependent diabetes. Herein, we discuss some of our recent efforts related to the study of miRNA in islet inflammation and islet engraftment. Our working hypothesis is that modulation of the expression of specific microRNAs in the transplant microenvironment will be of assistance in enhancing islet engraftment and promoting long-term function.

Original languageEnglish (US)
Pages (from-to)185-196
Number of pages12
JournalImmunologic Research
Volume57
Issue number1-3
DOIs
StatePublished - Dec 1 2013
Externally publishedYes

Fingerprint

Islets of Langerhans Transplantation
MicroRNAs
Messenger RNA
Research
Biological Phenomena
Gene Expression
Small Untranslated RNA
Drug Discovery
Type 1 Diabetes Mellitus
Genes
Biomarkers
Genome
RNA
Insulin
Inflammation
Transplants

Keywords

  • Autoimmunity
  • Bioengineering
  • Bioinformatics
  • Biomarker
  • Cell transplantation
  • Cellular therapies
  • Diabetes
  • Diabetes mellitus
  • Engraftment
  • Implantable device
  • Inflammation
  • Innate immunity
  • Islet transplantation
  • MicroRNA
  • Molecular target
  • Neovascularization
  • Rejection
  • Tissue engineering
  • Transplant microenvironment
  • Type 1 diabetes

ASJC Scopus subject areas

  • Immunology

Cite this

Pileggi, A., Klein, D., Fotino, C., Bravo-Egana, V., Rosero, S., Doni, M., ... Pastori, R. L. (2013). MicroRNAs in islet immunobiology and transplantation. Immunologic Research, 57(1-3), 185-196. https://doi.org/10.1007/s12026-013-8436-5

MicroRNAs in islet immunobiology and transplantation. / Pileggi, Antonello; Klein, Dagmar; Fotino, Carmen; Bravo-Egana, Valia; Rosero, Samuel; Doni, Marco; Podetta, Michele; Ricordi, Camillo; Molano, R. Damaris; Pastori, Ricardo L.

In: Immunologic Research, Vol. 57, No. 1-3, 01.12.2013, p. 185-196.

Research output: Contribution to journalArticle

Pileggi, A, Klein, D, Fotino, C, Bravo-Egana, V, Rosero, S, Doni, M, Podetta, M, Ricordi, C, Molano, RD & Pastori, RL 2013, 'MicroRNAs in islet immunobiology and transplantation', Immunologic Research, vol. 57, no. 1-3, pp. 185-196. https://doi.org/10.1007/s12026-013-8436-5
Pileggi A, Klein D, Fotino C, Bravo-Egana V, Rosero S, Doni M et al. MicroRNAs in islet immunobiology and transplantation. Immunologic Research. 2013 Dec 1;57(1-3):185-196. https://doi.org/10.1007/s12026-013-8436-5
Pileggi, Antonello ; Klein, Dagmar ; Fotino, Carmen ; Bravo-Egana, Valia ; Rosero, Samuel ; Doni, Marco ; Podetta, Michele ; Ricordi, Camillo ; Molano, R. Damaris ; Pastori, Ricardo L. / MicroRNAs in islet immunobiology and transplantation. In: Immunologic Research. 2013 ; Vol. 57, No. 1-3. pp. 185-196.
@article{5572ceef11284997ac1bd3e528c82eac,
title = "MicroRNAs in islet immunobiology and transplantation",
abstract = "The ultimate goal of diabetes therapy is the restoration of physiologic metabolic control. For type 1 diabetes, research efforts are focused on the prevention or early intervention to halt the autoimmune process and preserve β cell function. Replacement of pancreatic β cells via islet transplantation reestablishes physiologic β cell function in patients with diabetes. Emerging research shows that microRNAs (miRNAs), noncoding small RNA molecules produced by a newly discovered class of genes, negatively regulate gene expression. MiRNAs recognize and bind to partially complementary sequences of target messenger RNA (mRNA), regulating mRNA translation and affecting gene expression. Correlation between miRNA signatures and genome-wide RNA expression allows identification of multiple miRNA-mRNA pairs in biological processes. Because miRNAs target functionally related genes, they represent an exciting and indispensable approach for biomarkers and drug discovery. We are studying the role of miRNA in the context of islet immunobiology. Our research aims at understanding the mechanisms underlying pancreatic β cell loss and developing clinically relevant approaches for preservation and restoration of β cell function to treat insulin-dependent diabetes. Herein, we discuss some of our recent efforts related to the study of miRNA in islet inflammation and islet engraftment. Our working hypothesis is that modulation of the expression of specific microRNAs in the transplant microenvironment will be of assistance in enhancing islet engraftment and promoting long-term function.",
keywords = "Autoimmunity, Bioengineering, Bioinformatics, Biomarker, Cell transplantation, Cellular therapies, Diabetes, Diabetes mellitus, Engraftment, Implantable device, Inflammation, Innate immunity, Islet transplantation, MicroRNA, Molecular target, Neovascularization, Rejection, Tissue engineering, Transplant microenvironment, Type 1 diabetes",
author = "Antonello Pileggi and Dagmar Klein and Carmen Fotino and Valia Bravo-Egana and Samuel Rosero and Marco Doni and Michele Podetta and Camillo Ricordi and Molano, {R. Damaris} and Pastori, {Ricardo L.}",
year = "2013",
month = "12",
day = "1",
doi = "10.1007/s12026-013-8436-5",
language = "English (US)",
volume = "57",
pages = "185--196",
journal = "Immunologic Research",
issn = "0257-277X",
publisher = "Humana Press",
number = "1-3",

}

TY - JOUR

T1 - MicroRNAs in islet immunobiology and transplantation

AU - Pileggi, Antonello

AU - Klein, Dagmar

AU - Fotino, Carmen

AU - Bravo-Egana, Valia

AU - Rosero, Samuel

AU - Doni, Marco

AU - Podetta, Michele

AU - Ricordi, Camillo

AU - Molano, R. Damaris

AU - Pastori, Ricardo L.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - The ultimate goal of diabetes therapy is the restoration of physiologic metabolic control. For type 1 diabetes, research efforts are focused on the prevention or early intervention to halt the autoimmune process and preserve β cell function. Replacement of pancreatic β cells via islet transplantation reestablishes physiologic β cell function in patients with diabetes. Emerging research shows that microRNAs (miRNAs), noncoding small RNA molecules produced by a newly discovered class of genes, negatively regulate gene expression. MiRNAs recognize and bind to partially complementary sequences of target messenger RNA (mRNA), regulating mRNA translation and affecting gene expression. Correlation between miRNA signatures and genome-wide RNA expression allows identification of multiple miRNA-mRNA pairs in biological processes. Because miRNAs target functionally related genes, they represent an exciting and indispensable approach for biomarkers and drug discovery. We are studying the role of miRNA in the context of islet immunobiology. Our research aims at understanding the mechanisms underlying pancreatic β cell loss and developing clinically relevant approaches for preservation and restoration of β cell function to treat insulin-dependent diabetes. Herein, we discuss some of our recent efforts related to the study of miRNA in islet inflammation and islet engraftment. Our working hypothesis is that modulation of the expression of specific microRNAs in the transplant microenvironment will be of assistance in enhancing islet engraftment and promoting long-term function.

AB - The ultimate goal of diabetes therapy is the restoration of physiologic metabolic control. For type 1 diabetes, research efforts are focused on the prevention or early intervention to halt the autoimmune process and preserve β cell function. Replacement of pancreatic β cells via islet transplantation reestablishes physiologic β cell function in patients with diabetes. Emerging research shows that microRNAs (miRNAs), noncoding small RNA molecules produced by a newly discovered class of genes, negatively regulate gene expression. MiRNAs recognize and bind to partially complementary sequences of target messenger RNA (mRNA), regulating mRNA translation and affecting gene expression. Correlation between miRNA signatures and genome-wide RNA expression allows identification of multiple miRNA-mRNA pairs in biological processes. Because miRNAs target functionally related genes, they represent an exciting and indispensable approach for biomarkers and drug discovery. We are studying the role of miRNA in the context of islet immunobiology. Our research aims at understanding the mechanisms underlying pancreatic β cell loss and developing clinically relevant approaches for preservation and restoration of β cell function to treat insulin-dependent diabetes. Herein, we discuss some of our recent efforts related to the study of miRNA in islet inflammation and islet engraftment. Our working hypothesis is that modulation of the expression of specific microRNAs in the transplant microenvironment will be of assistance in enhancing islet engraftment and promoting long-term function.

KW - Autoimmunity

KW - Bioengineering

KW - Bioinformatics

KW - Biomarker

KW - Cell transplantation

KW - Cellular therapies

KW - Diabetes

KW - Diabetes mellitus

KW - Engraftment

KW - Implantable device

KW - Inflammation

KW - Innate immunity

KW - Islet transplantation

KW - MicroRNA

KW - Molecular target

KW - Neovascularization

KW - Rejection

KW - Tissue engineering

KW - Transplant microenvironment

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84891483568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891483568&partnerID=8YFLogxK

U2 - 10.1007/s12026-013-8436-5

DO - 10.1007/s12026-013-8436-5

M3 - Article

VL - 57

SP - 185

EP - 196

JO - Immunologic Research

JF - Immunologic Research

SN - 0257-277X

IS - 1-3

ER -